)

GlycoMimetics (GLYC) investor relations material
GlycoMimetics Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
GlycoMimetics ceased development of its drug candidates after negative Phase 3 and Phase 2 trial results for uproleselan in AML, with no statistically significant benefit observed and no ongoing clinical trials as of March 31, 2025.
The company initiated a strategic review, reduced its workforce by 80%, and entered into a merger agreement with Crescent Biopharma, expected to close in Q2 2025, after which Crescent's business will become primary.
A $200 million private placement is planned to close concurrently with the merger, with pre-merger GlycoMimetics shareholders expected to own only 2.6% of the combined company post-transaction.
Financial highlights
Net loss for Q1 2025 was $2.34 million, a significant improvement from a $10.74 million net loss in Q1 2024, reflecting the wind-down of operations.
Research and development expenses dropped to $15,000 in Q1 2025 from $6.03 million in Q1 2024; general and administrative expenses fell to $2.38 million from $5.09 million year-over-year.
Cash and cash equivalents were $5.6 million as of March 31, 2025, down from $10.7 million at year-end 2024.
Net cash used in operating activities was $5.1 million in Q1 2025, down from $10.5 million in Q1 2024.
No revenue was recognized in Q1 2025; the Apollomics license agreement was terminated effective May 21, 2025.
Outlook and guidance
Current cash is expected to fund operations until the merger closes; if the merger and private placement do not close by Q3 2025, the company may seek other alternatives or liquidate.
No plans to continue development of uproleselan or other drug candidates; Crescent Biopharma's pipeline will become the focus post-merger.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage